Dr. Mahdi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3990 John R 7 Brush North
Wayne State University Detroit Medical Centerobgyn
Detroit, MI 48201Phone+1 734-444-6406Fax+1 216-444-9423
Education & Training
Cleveland Clinic FoundationFellowship, Gynecologic Oncology, 2012 - 2015
University of WashingtonResidency, Obstetrics and Gynecology, 2009 - 2012
Wayne State University School of MedicineInternship, Transitional Year, 2008 - 2009
University of Al-Mustansiriyah College of MedicineClass of 2004
Certifications & Licensure
MI State Medical License 2008 - 2026
OH State Medical License 2012 - 2026
PA State Medical License 2020 - 2024- American Board of Obstetrics and Gynecology Obstetrics & Gynecology
- American Board of Obstetrics and Gynecology Gynecologic Oncology
Publications & Presentations
PubMed
- 37 citationsCeralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).Haider Mahdi, Navid Hafez, Deborah Blythe Doroshow, Davendra Sohal, Vickie L. Keedy
JCO Precision Oncology. 2021-09-07 - 9 citationsPARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer.Peter G. Rose, Meng Yao, Laura M. Chambers, Haider Mahdi, Robert Debernardo
Anti-Cancer Drugs. 2021-11-01 - 9 citationsDKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.Rebecca Arend, Jhalak Dholakia, Cesar Castro, Ursula Matulonis, Erika Hamilton
Gynecologic Oncology. 2023-05-01
Lectures
- The role of proinflammatory immune (IFN-gamma) gene signature in predicting prognosis and response to chemotherapy in uterine carcinoma.2019 ASCO Annual Meeting - 6/1/2019
- The role of different TGFβ signatures in predicting outcome in high grade serous ovarian carcinoma.2019 ASCO Annual Meeting - 6/1/2019
Press Mentions
ALX Oncology Doses First Patient in Trial of Evorpacept for Ovarian CancerMay 10th, 2023- ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Patients with Ovarian CancerMay 9th, 2023
- Zenith Epigenetics Announces Dosing of First Cancer Patient with a Combination of ZEN-3694 + Bristol Myers Squibb's Immune Checkpoint Inhibitor OPDIVOFebruary 22nd, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
